| |
Number of pts (%)
|
MOS (95% CI)
|
p
|
Hazard Ratio (95% CI)
|
HCS (95% CI)
|
|---|
|
RPA
| | | | | |
|
1
|
26 (10.4)
|
25.6 M (18.4–32.9)
| |
1
|
0.6783
|
|
2
|
166 (66.4)
|
10.4 M (8.9–12.6)
|
<0.001
|
2.16 (1.34–3.50)
|
(0.65–0.71)
|
|
3
|
58 (23.2)
|
2 M (1.4–3.1)
| |
11.38 (6.57–19.70)
| |
|
GPA
| | | | | |
|
≥3
|
32 (12.8)
|
24.7 M (12.7–27.1)
| |
1
|
0.658
|
|
1.5-2.5
|
116 (46.4)
|
12.3 M (10.1–15.1)
|
<0.001
|
1.70 (1.09–2.65)
|
(0.62–0.69)
|
|
0-1
|
102 (40.8)
|
4.2 M (3.1–5.4)
| |
4.15 (2.62–6.55)
| |
|
BS-BM
| | | | | |
|
3
|
31 (12.4)
|
21.6 M (12.7–25.8)
|
<0.001
|
1
| |
|
2
|
68 (27.2)
|
12.7 M (9.7–18.4)
| |
1.30 (0.81–2.08)
|
0.6803
|
|
1
|
96 (38.4)
|
8.7 M (6.1–12.3)
| |
2.20 (1.41–3.46)
|
(0.64–0.72)
|
|
0
|
55 (22.0)
|
2.2 M (1.4–3.6)
| |
6.99 (4.25–11.47)
| |
|
P1PS
| | | | | |
|
0–1
|
95 (38.0)
|
16.4 M (11.9–23.3)
| |
1
|
0.6251
|
|
2–3
|
64 (25.6)
|
5.9 M (3.4–8.4)
|
<0.001
|
2.89 (2.01–4.14)
|
(0.58–0.66)
|
|
Not available
|
91 (36.4)
| | | | |
|
Breast GPA
| | | | | |
|
3.5-4
|
53 (21.2)
|
18.4 M (12.4–23.3)
| |
1
|
0.6587
|
|
3
|
90 (36.0)
|
10.3 M (8.4–13.7)
|
<0.001
|
1.37 (0.95–2.00)
|
(0.62–0.69)
|
|
1.5-2.5
|
76 (30.4)
|
5.7 M (4–8)
| |
2.09 (1.43–3.06)
| |
|
0-1
|
31 (12.4)
|
2.3 M (1–4.1)
| |
5.75 (3.56–9.27)
| |
|
Breast RPA
| | | | | |
|
1
|
20 (8.0)
|
21.3 M (9.7–53.9)
| |
1
|
0.6037
|
|
2
|
192 (76.8)
|
9.8 M (8.4–12.1)
|
<0.001
|
2.05 (1.20–3.50)
|
(0.57–0.63)
|
|
3
|
38 (15.2)
|
2.3 M (1.8–4.3)
| |
6.84 (3.69–12.72)
| |
|
Le Scodan Score
| | | | | |
|
1
|
89 (35.6)
|
15.2 M (11.5–19.4)
| |
1
|
0.6239
|
|
2
|
49 (19.6)
|
9.7 M (7.5–12.4)
|
<0.001
|
1.32 (0.91–1.92)
|
(0.58–0.66)
|
|
3
|
112 (44.8)
|
4.2 M (3.3–6.1)
| |
1.92 (1.43–2.59)
| |
-
CI, Confidence Interval. MOS, Median Overall Survival (from brain metastases diagnosis). M, months. Pts, patients.
